Boston Scientific Corp
I · AI-analyse
In het kort
Boston Scientific designs and sells specialized medical equipment that doctors use during minimally-invasive procedures — think catheters, stents, implants, and electronic devices that treat conditions in the heart, digestive tract, urinary system, and nervous system [Boston Scientific]. Their products help cardiologists open blocked arteries, urologists treat bladder problems, and pain specialists manage chronic pain through implanted nerve stimulators [Boston Scientific].
Boston Scientific is a $84.4 billion medical device company that makes products for heart procedures, digestive system treatments, urology, and pain management [Yahoo Finance]. The company reported strong revenue growth of 19.9% year-over-year and recently announced a $2 billion share buyback alongside a $1.5 billion investment in MiRus, a company developing a new heart valve technology [Yahoo Finance]. Recent clinical trial success with its SEISMIQ 4CE device for treating severely calcified heart arteries positions the company well in a challenging cardiac niche [Simply Wall St].
Boston Scientific is financially stable with strong cash generation, though debt levels are moderate and returns on invested capital remain below 10% [Yahoo Finance].
Sentinellis-score
6.3/10
Moderate concerns
Marktkapitalisatie
$84.4B
Omzet (12 maanden)
$20.1B
II · Recent nieuws
Wat de koers bewoog
6 stories · ranked by relevance
- macro2026-05-20
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
Simply Wall St
- macro2026-05-20
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Yahoo Finance
- macro2026-05-20
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Yahoo Finance
- macro2026-05-19
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Yahoo Finance
- macro2026-05-19
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Yahoo Finance
- macro2026-05-18
Boston Scientific announces strategic investment in MiRus LLC
Yahoo Finance
Premium · gratis met elk account
The company's stock underperformed in Q1 2026 as part of broader market weakness driven by geopolitical conflicts, private credit concerns, government shutdown, and AI uncertainty, with Boston Scientific being among top holdings in funds that lost over 11% during the period [Yahoo Finance].
Risico's
4
Kansen
6
Leiding
10
Nog 19 bevindingen in het volledige rapport — gratis met elk account.
Ontgrendel de volledige analyse van Boston Scientific Corp
Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.
- 4 risico's en 6 kansen — elk met zijn bron
- Meer dan 100 financiële cijfers met grafieken en vergelijkingen
- Volledige nieuwssamenvattingen met bronlinks
- Directie en beloning
- PDF-export voor offline
III · Vergelijkbare bedrijven
Misschien ook interessant
Same sector · Healthcare or comparable health
Op je volglijst zetten?